(Q53779084)

English

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Comple

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Vladimir Moiseyenko

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

David Cunningham

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Josep Tabernero Caturla

23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Eric Van Cutsem

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Florence Joulain

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Paulo M Hoff

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Edith Mitchell

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Paul Ruff

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Radek Lakomý

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Jana Prausová

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Guy van Hazel

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Hans-Joachim Schmoll

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Albert J Ten Tije

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Joseph McKendrick

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Hendrik Kröning

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Yves Humblet

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Cristina Grávalos

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Solenn Le-Guennec

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Michael Andria

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Emmanuelle Dochy

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Raghu L Vishwanath

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Teresa Macarulla

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

1 June 2016

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Targeted oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

383-400

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

https://scigraph.springernature.com/pub.10.1007/s11523-015-0402-9

0 references

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

Bevacizumab for the treatment of glioblastoma.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

VEGF-Trap: a VEGF blocker with potent antitumor effects

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab'.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0402-9

21 January 2018

The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26706237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

1 reference

https://pubmed.ncbi.nlm.nih.gov/26706237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?

1 reference

https://pubmed.ncbi.nlm.nih.gov/26706237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11523-015-0402-9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26706237%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53779084&oldid=1508997698"